• Hikma Pharmaceuticals won a unanimous U.S. Supreme Court ruling that effectively ends Amarin’s patent-infringement litigation.
• The case centered on Hikma’s generic icosapent ethyl, launched in 2020 with a “skinny label” that carved out patented indications for Vascepa.
• Amarin alleged the generic was marketed for patented uses; a district court dismissal was revived on appeal before Hikma took the dispute to the Supreme Court.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.